🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. ASP3082, DEXTROSE INJECTION / BRADEX 5%

    The George Institute

    Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. ASP5541, ABIRATERONE ACETATE, PREDNISOLONE, PREDNISONE

    Astellas Pharma GmbH

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  3. ASP8951, Calcium Folinate 10 mg/ml Injection, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Fluorouracil 50mg/ml Injection., OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.

    Astellas Pharma GmbH

    Advanced cancer of the stomach or the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  4. ASP8951, PACLITAXEL, GEMCITABINE

    Astellas Pharma GmbH

    First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.

    phase 2 small molecule active

    1 trial

  5. ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 2 small molecule active

    1 trial

  6. ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule active

    1 trial

  7. AST-OPC1

    Lineage Cell Therapeutics

    Cervical Spinal Cord Injury

    phase 2 mab completed

    1 trial

  8. ASTX727, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Taiho Pharma Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  9. ASTX727, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Fondazione Telethon ETS

    MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy

    phase 2 small molecule active

    1 trial

  10. AT-1501

    Eledon Pharmaceuticals

    Prevention of Rejection in Kidney Transplant

    phase 2 small molecule active

    1 trial

  11. AT-1501

    Eledon Pharmaceuticals

    Kidney Transplant Rejection

    phase 2 small molecule active

    2 trials

  12. AT-1501

    Eledon Pharmaceuticals

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  13. AT-1501

    Eledon Pharmaceuticals

    IgA Nephropathy

    phase 2 small molecule terminated

    1 trial

  14. AT-1501

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  15. AT-1501 IV Infusion

    Eledon Pharmaceuticals

    Brittle Type 1 Diabetes Mellitus

    phase 2 mab terminated

    1 trial

  16. AT-527

    Atea Pharmaceuticals

    COVID-19

    phase 2 small molecule terminated

    2 trials

  17. ATA188

    Evidence Based Cataract Study Group

    Primary Progressive Multiple Sclerosis

    phase 2 mab terminated

    1 trial

  18. ATEZOLIZUMAB

    The George Institute

    Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)

    phase 2 small molecule active

    1 trial

  19. ATH434 dose level 1

    ALTERITY THERAPEUTICS LTD

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  20. ATH434-DP2

    ALTERITY THERAPEUTICS LTD

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  21. ATI-045, Placebo to ATI-045

    Aclaris Therapeutics

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  22. ATI-1777

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  23. ATI-1777 2.0% w/w

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  24. ATI-2138

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources